NMT2 and cancer: Collectively, our epigenetic, proteomic, metabolomic, and transcriptomic analyses revealed that numerous factors contribute to the sensitivity of cancer cells to myristoylation inhibition, including the loss of NMT2, dependency on NMT1, and increased expression of a gene set encompassing 54 genes that we named MISS-54.